Table 1.

Malaria antigen and antibody ELISA results were compared in confirmed P. vivax patients and healthy controls

ELISA	P. vivax patients		Posttreatment follow-up						Healthy controls
	<1 week		1 – 3 months		4 – 6 months		7 – 9 months
	n (s%)	mean S/CO	n (s%)	mean S/CO	n (s%)	mean S/CO	n (s%)	mean S/CO	n (s%)	mean S/CO
Antigen
Positive	284 (94.7)	26.7 ± 15.42	0	–	0	–	0	–	5 (0.7)	2.39 ± 0.10
Negative	16 (5.4)	0.63 ± 0.17	22 (100)	0.29 ± 0.10	16 (100)	0.30 ± 0.11	3 (100)	0.20 ± 0.06	724 (99.3)	0.19 ± 0.19
Total	300 (100)	25.39 ± 16.07	22 (100)	0.29 ± 0.10	16 (100)	0.30 ± 0.11	3 (100)	0.20 ± 0.06	729 (100)	0.2 ± 0.27
Antibody
Positive	282 (94.0)	14.43 ± 6.15	15 (61)	5.11 ± 5.29	9 (56.3)	4.66 ± 3.96	1 (33)	8.04	12 (1.6)	4.24 ± 3.55
Negative	18 (6)	0.35 ± 0.08	7 (39)	0.35 ± 0.08	7 (43.8)	0.43 ± 0.13	2 (67)	0.25 ± 0.02	717 (98.4)	0.27 ± 0.11
Total	300 (100)	13.59 ± 6.84	22 (100)	5.58 ± 5.43	16 (100)	3.07 ± 3.72	3 (100)	2.86 ± 4.49	729 (100)	0.34 ± 0.69

S/CO = Signal to cutoff ratio.